List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6604186/publications.pdf Version: 2024-02-01

		13865	11308
297	22,620	67	136
papers	citations	h-index	g-index
317	317	317	25262
all docs	docs citations	times ranked	citing authors

HÃYKAN L OLSSON

#	Article	IF	CITATIONS
1	Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402.	7.4	1,898
2	Gene-Expression Profiles in Hereditary Breast Cancer. New England Journal of Medicine, 2001, 344, 539-548.	27.0	1,669
3	Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature, 2020, 577, 561-565.	27.8	1,209
4	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099
5	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711
6	Oral Contraceptives and the Risk of Hereditary Ovarian Cancer. New England Journal of Medicine, 1998, 339, 424-428.	27.0	591
7	Association Between <emph type="ital">BRCA1</emph> and <emph type="ital">BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 382.</emph 	7.4	546
8	A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature, 2011, 480, 94-98.	27.8	466
9	Genome-wide association study identifies three loci associated with melanoma risk. Nature Genetics, 2009, 41, 920-925.	21.4	422
10	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
11	Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2002, 94, 1773-1779.	6.3	318
12	Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nature Genetics, 2008, 40, 102-107.	21.4	316
13	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
14	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
15	Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Research, 2010, 12, R36.	5.0	251
16	Tamoxifen and contralateral breast cancer inBRCA1 andBRCA2 carriers: An update. International Journal of Cancer, 2006, 118, 2281-2284.	5.1	246
17	Genome-wide association study identifies three new melanoma susceptibility loci. Nature Genetics, 2011, 43, 1108-1113.	21.4	230
18	Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. International Journal of Epidemiology, 2009, 38, 814-830.	1.9	219

#	Article	IF	CITATIONS
19	Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nature Genetics, 2015, 47, 987-995.	21.4	218
20	Common sequence variants on 20q11.22 confer melanoma susceptibility. Nature Genetics, 2008, 40, 838-840.	21.4	209
21	The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Research, 2016, 76, 2778-2790.	0.9	208
22	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	21.4	184
23	Genetic insights into biological mechanisms governing human ovarian ageing. Nature, 2021, 596, 393-397.	27.8	183
24	Molecular classification of familial non- <i>BRCA1/BRCA2</i> breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2532-2537.	7.1	182
25	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	12.8	178
26	Use of Sunbeds or Sunlamps and Malignant Melanoma in Southern Sweden. American Journal of Epidemiology, 1994, 140, 691-699.	3.4	177
27	Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer, 1998, 83, 310-319.	4.1	170
28	Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Research, 2010, 12, R42.	5.0	167
29	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
30	Selection criteria for genetic assessment of patients with familial melanoma. Journal of the American Academy of Dermatology, 2009, 61, 677.e1-677.e14.	1.2	154
31	Effect of pregnancy as a risk factor for breast cancer in <i>BRCA1</i> / <i>BRCA2</i> mutation carriers. International Journal of Cancer, 2005, 117, 988-991.	5.1	152
32	Tamoxifen and Risk of Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Journal of Clinical Oncology, 2013, 31, 3091-3099.	1.6	148
33	Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget, 2015, 6, 12297-12309.	1.8	148
34	Distinct Genomic Profiles in Hereditary Breast Tumors Identified by Array-Based Comparative Genomic Hybridization. Cancer Research, 2005, 65, 7612-7621.	0.9	147
35	Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer, 2003, 97, 1387-1392.	4.1	145
36	Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nature Genetics, 2011, 43, 1114-1118.	21.4	140

#	Article	IF	CITATIONS
37	Germline Mutation in <i>BRCA1</i> or <i>BRCA2</i> and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. Clinical Cancer Research, 2015, 21, 652-657.	7.0	138
38	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nature Genetics, 2020, 52, 494-504.	21.4	138
39	Oral Contraceptives and Breast Cancer Risk in the International <i>BRCA1/2</i> Carrier Cohort Study: A Report From EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. Journal of Clinical Oncology, 2007, 25, 3831-3836.	1.6	137
40	Nonsense Mutations in the Shelterin Complex Genes ACD and TERF2IP in Familial Melanoma. Journal of the National Cancer Institute, 2015, 107, .	6.3	134
41	Anthropometric and Hormonal Risk Factors for Male Breast Cancer: Male Breast Cancer Pooling Project Results. Journal of the National Cancer Institute, 2014, 106, djt465-djt465.	6.3	131
42	Reproductive and Hormonal Factors, and Ovarian Cancer Risk for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the International <i>BRCA1/2</i> Carrier Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 601-610.	2.5	130
43	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
44	Sunscreen use and malignant melanoma. International Journal of Cancer, 2000, 87, 145-150.	5.1	119
45	<i><scp>NF</scp>1</i> â€mutated melanoma tumors harbor distinct clinical and biological characteristics. Molecular Oncology, 2017, 11, 438-451.	4.6	112
46	Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers. Lancet, The, 1998, 352, 1359-1360.	13.7	111
47	A variant in FTO shows association with melanoma risk not due to BMI. Nature Genetics, 2013, 45, 428-432.	21.4	111
48	The Effect on Melanoma Risk of Genes Previously Associated With Telomere Length. Journal of the National Cancer Institute, 2014, 106, .	6.3	109
49	Genetic testing for melanoma. Lancet Oncology, The, 2002, 3, 653-654.	10.7	106
50	Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. European Journal of Cancer, 2008, 44, 472-480.	2.8	106
51	Correlation between p53, c-erbB-2, and topoisomerase II? expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. , 1999, 187, 207-216.		103
52	c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. International Journal of Cancer, 1992, 51, 687-691.	5.1	102
53	Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker. Breast Cancer Research, 2012, 14, R31.	5.0	100
54	High folate intake is associated with lower breast cancer incidence in postmenopausal women in the Malmö Diet and Cancer cohort. American Journal of Clinical Nutrition, 2007, 86, 434-443.	4.7	99

#	Article	IF	CITATIONS
55	Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. Nature Genetics, 2012, 44, 1182-1184.	21.4	99
56	Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma. Clinical Cancer Research, 2012, 18, 4026-4036.	7.0	96
57	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
58	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
59	Early Oral Contraceptive Use and Breast Cancer Among Premenopausal Women: Final Report From a Study in Southern Sweden. Journal of the National Cancer Institute, 1989, 81, 1000-1004.	6.3	86
60	Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma. Cancer Research, 2016, 76, 4765-4774.	0.9	86
61	A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. International Journal of Cancer, 2009, 124, 420-428.	5.1	84
62	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	1.9	81
63	Chromosome I alterations in breast cancer: Allelic loss on Ip and Iq Is related to lymphogenic metastases and poor prognosis. Genes Chromosomes and Cancer, 1992, 5, 311-320.	2.8	80
64	Anxiety and Depression in Breast Cancer Patients at Start of Adjuvant Radiotherapy: Relations to age and type of surgery. Acta Oncológica, 1992, 31, 641-643.	1.8	78
65	Postmenopausal breast cancer is associated with high intakes of omega6 fatty acids (Sweden). Cancer Causes and Control, 2002, 13, 883-893.	1.8	76
66	The relationship between lifestyle factors and venous thromboembolism among women: a report from the MISS study. British Journal of Haematology, 2009, 144, 234-240.	2.5	75
67	High risk of tobacco-related cancers in <i>CDKN2A</i> mutation-positive melanoma families. Journal of Medical Genetics, 2014, 51, 545-552.	3.2	73
68	Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes and Control, 2005, 16, 667-674.	1.8	71
69	High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast Cancer Research and Treatment, 2011, 129, 747-760.	2.5	70
70	A prospective study on dietary fat and incidence of prostate cancer (Malmö, Sweden). Cancer Causes and Control, 2007, 18, 1107-1121.	1.8	68
71	Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14252-14257.	7.1	68
72	Head Trauma and Exposure to Prolactin-Elevating Drugs as Risk Factors for Male Breast Cancer. Journal of the National Cancer Institute, 1988, 80, 679-683.	6.3	67

#	Article	IF	CITATIONS
73	Familial Breast and Ovarian Cancer: A Swedish Population-based Register Study. American Journal of Epidemiology, 2000, 152, 1154-1163.	3.4	66
74	Alcohol Drinking May Increase Risk of Breast Cancer in Men: A European Population-Based Case–Control Study. Cancer Causes and Control, 2004, 15, 571-580.	1.8	66
75	The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma. Cell Reports, 2019, 27, 3573-3586.e7.	6.4	66
76	Reproducibility of a Self-Administered Questionnaire for Assessment of Melanoma Risk. International Journal of Epidemiology, 1996, 25, 245-251.	1.9	63
77	Mapping of a Novel Ocular and Cutaneous Malignant Melanoma Susceptibility Locus to Chromosome 9q21.32. Journal of the National Cancer Institute, 2005, 97, 1377-1382.	6.3	63
78	Occupational Exposures and Non-Hodgkin's Lymphoma in Southern Sweden. International Journal of Occupational and Environmental Health, 2004, 10, 13-21.	1.2	61
79	Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors. International Journal of Cancer, 2006, 119, 1052-1060.	5.1	59
80	Folate Intake, Methylenetetrahydrofolate Reductase Polymorphisms, and Breast Cancer Risk in Women from the Malmol^ Diet and Cancer Cohort. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1101-1110.	2.5	59
81	Influence on the Health of the Partner Affected by Tumor Disease in the Wife or Husband Based on a Population-Based Register Study of Cancer in Sweden. Journal of Clinical Oncology, 2009, 27, 4781-4786.	1.6	58
82	Molecular and genetic diversity in the metastatic process of melanoma. Journal of Pathology, 2014, 233, 39-50.	4.5	58
83	Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. European Journal of Cancer, 2005, 41, 2312-2320.	2.8	57
84	A prospective, populationâ€based study of 40,000 women regarding host factors, UV exposure and sunbed use in relation to risk and anatomic site of cutaneous melanoma. International Journal of Cancer, 2012, 131, 706-715.	5.1	56
85	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
86	Flow Cytometric DNA Index and S-Phase Fraction in Breast Cancer in Relation to Other Prognostic Variables and to Clinical Outcome. Acta OncolÃ ³ gica, 1992, 31, 157-165.	1.8	53
87	Are active sun exposure habits related to lowering risk of type 2 diabetes mellitus in women, a prospective cohort study?. Diabetes Research and Clinical Practice, 2010, 90, 109-114.	2.8	53
88	Increased cancer risks among arthroplasty patients: 30year follow-up of the Swedish Knee Arthroplasty Register. European Journal of Cancer, 2011, 47, 1061-1071.	2.8	52
89	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	6.4	52
90	Image cytometric DNA analysis in human breast cancer analysis may add prognostic information in diploid cases with low S-Phase fraction by flow cytometry. Cytometry, 1992, 13, 577-585.	1.8	51

#	Article	IF	CITATIONS
91	Correlation between karyotypic pattern and clinicopathologic features in 125 breast cancer cases. , 1996, 66, 191-196.		51
92	Somatic genetic alterations inBRCA2-associated and sporadic male breast cancer. Genes Chromosomes and Cancer, 1999, 24, 56-61.	2.8	50
93	Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden. Cancer Causes and Control, 2012, 23, 769-777.	1.8	49
94	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.9	49
95	High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer. Breast Cancer Research and Treatment, 2014, 147, 571-578.	2.5	47
96	Germline <i>CDKN2A</i> Mutation Status and Survival in Familial Melanoma Cases. Journal of the National Cancer Institute, 2016, 108, djw135.	6.3	47
97	Plant foods and oestrogen receptor Â- and Â-defined breast cancer: observations from the Malmo Diet and Cancer cohort. Carcinogenesis, 2008, 29, 2203-2209.	2.8	45
98	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. Journal of the National Cancer Institute, 2021, 113, 329-337.	6.3	45
99	Characterization of a Novel Breast Carcinoma Xenograft and Cell Line Derived from a BRCA1 Germ-Line Mutation Carrier. Laboratory Investigation, 2003, 83, 387-396.	3.7	43
100	Risk factors for extrahepatic biliary tract carcinoma in men: medical conditions and lifestyle. European Journal of Gastroenterology and Hepatology, 2007, 19, 623-630.	1.6	43
101	Increased breast cancer risk at high plasma folate concentrations among women with the MT HFR 677T allele. American Journal of Clinical Nutrition, 2009, 90, 1380-1389.	4.7	43
102	Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study. BMC Cancer, 2009, 9, 140.	2.6	43
103	A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer. Molecular and Cellular Proteomics, 2019, 18, 1836-1850.	3.8	42
104	Galectin-1-Binding Glycoforms of Haptoglobin with Altered Intracellular Trafficking, and Increase in Metastatic Breast Cancer Patients. PLoS ONE, 2011, 6, e26560.	2.5	41
105	The Retinoblastoma Gene Undergoes Rearrangements in <i>BRCA1</i> -Deficient Basal-like Breast Cancer. Cancer Research, 2012, 72, 4028-4036.	0.9	41
106	Sickness absence among cancer patients in the pre-diagnostic and the post-diagnostic phases of five common forms of cancer. Supportive Care in Cancer, 2012, 20, 741-747.	2.2	41
107	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2020, 22, 8.	5.0	41
108	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116.	6.3	40

#	Article	IF	CITATIONS
109	Haplotype analysis and age estimation of the 113insRCDKN2A founder mutation in Swedish melanoma families. Genes Chromosomes and Cancer, 2001, 31, 107-116.	2.8	39
110	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	6.2	39
111	Impact of Pregestational Weight and Weight Gain during Pregnancy on Long-Term Risk for Diseases. PLoS ONE, 2017, 12, e0168543.	2.5	39
112	The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response. Cancers, 2020, 12, 742.	3.7	38
113	Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2mutation status. Breast Cancer Research, 2003, 5, R175-86.	5.0	37
114	Association of the Variants <i>CASP8</i> D302H and <i>CASP10</i> V410I with Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2859-2868.	2.5	37
115	Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985. Cancer, 1997, 79, 275-283.	4.1	35
116	Plasma Folate Concentrations Are Positively Associated with Risk of Estrogen Receptor Î ² Negative Breast Cancer in a Swedish Nested Case Control Study. Journal of Nutrition, 2010, 140, 1661-1668.	2.9	35
117	Low Cancer Rates among Patients with Dementia in a Population-Based Register Study in Sweden. Dementia and Geriatric Cognitive Disorders, 2010, 30, 39-42.	1.5	35
118	Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228 951 Women of European Descent. Journal of the National Cancer Institute, 2020, 112, 295-304.	6.3	35
119	The Protective Association of High Plasma Enterolactone with Breast Cancer Is Reasonably Robust in Women with Polymorphisms in the Estrogen Receptor α and β Genes. Journal of Nutrition, 2009, 139, 993-1001.	2.9	34
120	Ovarian cancer susceptibility alleles and risk of ovarian cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. Human Mutation, 2012, 33, 690-702.	2.5	34
121	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. American Journal of Obstetrics and Gynecology, 2021, 225, 51.e1-51.e17.	1.3	34
122	The regulatory and basal phosphorylation sites of hormone-sensitive lipase are dephosphorylated by protein phosphatase-1, 2A and 2C but not by protein phosphatase-2B. FEBS Journal, 1987, 168, 399-405.	0.2	33
123	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectrum, 2018, 2, pky023.	2.9	33
124	Clinical protein science in translational medicine targeting malignant melanoma. Cell Biology and Toxicology, 2019, 35, 293-332.	5.3	33
125	Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline <i>CDKN2A</i> mutations. Journal of Medical Genetics, 2020, 57, 316-321.	3.2	33
126	Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes. Familial Cancer, 2008, 7, 331-337.	1.9	32

#	Article	IF	CITATIONS
127	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747.	2.9	32
128	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
129	Overall cancer incidence not increased after prosthetic knee replacement: 14,551 patients followed for 66,622 person-years. , 1996, 68, 30-33.		30
130	Somatic frameshift alterations in mononucleotide repeatâ€containing genes in different tumor types from an HNPCC family with germline MSH2 mutation. Genes Chromosomes and Cancer, 2000, 29, 33-39.	2.8	30
131	Cytogenetic studies in non-Hodgkin lymphomas-Results from fineneedle aspiration samples. Hereditas, 1985, 103, 63-76.	1.4	30
132	Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions. International Journal of Cancer, 2015, 136, 1351-1360.	5.1	30
133	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	12.8	30
134	Multiple metastases from cutaneous malignant melanoma patients may display heterogeneous genomic and epigenomic patterns. Melanoma Research, 2010, 20, 381-391.	1.2	30
135	One or multiple samplings for flow cytometric DNA analyses in breast cancer-prognostic implications?. Cytometry, 1992, 13, 241-249.	1.8	29
136	High fat and alcohol intakes are risk factors of postmenopausal breast cancer: A prospective study from the Malmö diet and cancer cohort. International Journal of Cancer, 2004, 110, 589-597.	5.1	29
137	Do both heterocyclic amines and omegaâ€6 polyunsaturated fatty acids contribute to the incidence of breast cancer in postmenopausal women of the Malmö diet and cancer cohort?. International Journal of Cancer, 2008, 123, 1637-1643.	5.1	29
138	Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status. Journal of the American Academy of Dermatology, 2017, 77, 893-901.	1.2	29
139	Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma. Molecular Oncology, 2020, 14, 933-950.	4.6	29
140	Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine. Translational Oncology, 2021, 14, 101029.	3.7	29
141	Enterolactone Is Differently Associated with Estrogen Receptor β–Negative and –Positive Breast Cancer in a Swedish Nested Case-Control Study. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3241-3251.	2.5	28
142	A new look at drugs targeting malignant melanoma—An application for mass spectrometry imaging. Proteomics, 2014, 14, 1963-1970.	2.2	28
143	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	5.2	28
144	Correlation of histopathologic characteristics to protein expression and function in malignant melanoma. PLoS ONE, 2017, 12, e0176167.	2.5	27

#	Article	IF	CITATIONS
145	Phosphorylation of the basal site of hormone-sensitive lipase by glycogen synthase kinase-4. FEBS Letters, 1986, 209, 175-180.	2.8	26
146	hMLH1, hMSH2 andhMSH6 mutations in hereditary non-polyposis colorectal cancer families from Southern Sweden. , 1999, 83, 197-202.		26
147	Occupational factors and risk of adult bone sarcomas: A multicentric case-control study in Europe. International Journal of Cancer, 2006, 118, 721-727.	5.1	26
148	Genomic alterations in histopathologically normal breast tissue from <i>BRCA1</i> mutation carriers may be caused by BRCA1 haploinsufficiency. Genes Chromosomes and Cancer, 2010, 49, 78-90.	2.8	26
149	The clinicopathological and gene expression patterns associated with ulceration of primary melanoma. Pigment Cell and Melanoma Research, 2015, 28, 94-104.	3.3	26
150	Chromosome aberrations in prophylactic mastectomies from women belonging to breast cancer families. , 1996, 16, 185-188.		25
151	Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2mutation carriers. Breast Cancer Research, 2010, 12, R102.	5.0	25
152	An inherited variant in the gene coding for vitamin <scp>D</scp> â€binding protein and survival from cutaneous melanoma: a <scp>B</scp> io <scp>G</scp> eno <scp>MEL</scp> study. Pigment Cell and Melanoma Research, 2014, 27, 234-243.	3.3	25
153	Development and Validation of a Melanoma Risk Score Based on Pooled Data from 16 Case–Control Studies. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 817-824.	2.5	25
154	Hypophyseal tumor and gynecomastia preceding bilateral breast cancer development in a man. Cancer, 1984, 53, 1974-1977.	4.1	24
155	Genetic variant of the human homologous recombination-associated gene RMI1 (S455N) impacts the risk of AML/MDS and malignant melanoma. Cancer Letters, 2007, 258, 38-44.	7.2	24
156	Different fractions of human serum glycoproteins bind galectin-1 or galectin-8, and their ratio may provide a refined biomarker for pathophysiological conditions in cancer and inflammatory disease. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 1366-1372.	2.4	24
157	Inherited variation in the PARP1 gene and survival from melanoma. International Journal of Cancer, 2014, 135, 1625-1633.	5.1	24
158	Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations. Human Genetics, 2016, 135, 1241-1249.	3.8	24
159	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 368-378.	2.5	24
160	A Nonsynonymous Polymorphism in <i>IRS1</i> Modifies Risk of Developing Breast and Ovarian Cancers in <i>BRCA1</i> and Ovarian Cancer in <i>BRCA2</i> Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370.	2.5	23
161	Metal-on-metal joint bearings and hematopoetic malignancy. Monthly Notices of the Royal Astronomical Society: Letters, 2012, 83, 553-558.	3.3	23
162	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23

#	Article	IF	CITATIONS
163	Cutaneous malignant melanoma in South Sweden 1965, 1975, and 1985. A histopathologic review. Cancer, 1994, 73, 1625-1630.	4.1	22
164	High <i><scp>TERT</scp></i> promoter mutation frequency in nonâ€acral cutaneous metastatic melanoma. Pigment Cell and Melanoma Research, 2016, 29, 598-600.	3.3	22
165	Tumor genetic heterogeneity analysis of chronic sunâ€damaged melanoma. Pigment Cell and Melanoma Research, 2020, 33, 480-489.	3.3	22
166	Multiple metastases from cutaneous malignant melanoma patients may display heterogeneous genomic and epigenomic patterns. Melanoma Research, 2010, 20, 381-91.	1.2	22
167	Epithelial and Stromal MicroRNA Signatures of Columnar Cell Hyperplasia Linking Let-7c to Precancerous and Cancerous Breast Cancer Cell Proliferation. PLoS ONE, 2014, 9, e105099.	2.5	21
168	Occupational sedentariness and breast cancer risk. Acta Oncológica, 2017, 56, 75-80.	1.8	21
169	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI Cancer Spectrum, 2018, 2, pky078.	2.9	21
170	Risk factors for subarachnoid haemorrhage: a nationwide cohort of 950Â000 adults. International Journal of Epidemiology, 2019, 48, 2018-2025.	1.9	21
171	Genetic Predisposition to Breast Cancer. Acta OncolÃ ³ gica, 1996, 35, 1-8.	1.8	20
172	Plasma Alkylresorcinol Metabolites as Biomarkers for Whole-Grain Intake and Their Association with Prostate Cancer: A Swedish Nested Case–Control Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 73-83.	2.5	20
173	Desloratadine and loratadine stand out among common H ₁ -antihistamines for association with improved breast cancer survival. Acta Oncológica, 2020, 59, 1103-1109.	1.8	20
174	The Human Melanoma Proteome Atlas—Complementing the melanoma transcriptome. Clinical and Translational Medicine, 2021, 11, e451.	4.0	20
175	Analysis of Alpha-Synuclein in Malignant Melanoma – Development of a SRM Quantification Assay. PLoS ONE, 2014, 9, e110804.	2.5	20
176	<scp><i>CDKN2a</i></scp> mutationâ€negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies. International Journal of Cancer, 2015, 137, 2220-2226.	5.1	19
177	A Protein Deep Sequencing Evaluation of Metastatic Melanoma Tissues. PLoS ONE, 2015, 10, e0123661.	2.5	19
178	Tobacco and Alcohol in Relation to Male Breast Cancer: An Analysis of the Male Breast Cancer Pooling Project Consortium. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 520-531.	2.5	19
179	Accuracy of self-reported family history of cancer, mutation status and tumor characteristics in patients with early onset breast cancer. Acta OncolÃ ³ gica, 2018, 57, 595-603.	1.8	19
180	Multiple Primary Melanoma Incidence Trends Over Five Decades: A Nationwide Population-Based Study. Journal of the National Cancer Institute, 2021, 113, 318-328.	6.3	19

#	Article	IF	CITATIONS
181	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	12.8	19
182	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 623-642.	2.5	19
183	Time to Diagnosis of Melanoma: Same Trend in Different Continents. Journal of Cutaneous Medicine and Surgery, 2007, 11, 137-144.	1.2	18
184	Somatic BRAF and NRAS Mutations in Familial Melanomas with Known Germline CDKN2A Status: A GenoMEL Study. Journal of Investigative Dermatology, 2014, 134, 287-290.	0.7	18
185	Germline Variation at CDKN2A and Associations with Nevus Phenotypes amongÂMembers of Melanoma Families. Journal of Investigative Dermatology, 2017, 137, 2606-2612.	0.7	18
186	Estrogen receptor content in malignant breast tumors in mena review. , 2000, 5, 283-287.		17
187	Fat From Different Foods Show Diverging Relations With Breast Cancer Risk in Postmenopausal Women. Nutrition and Cancer, 2005, 53, 135-143.	2.0	17
188	In-Source Decay Causes Artifacts in SELDI-TOF MS Spectra. Journal of Proteome Research, 2007, 6, 1609-1614.	3.7	17
189	Perceptions of genetic research and testing among members of families with an increased risk of malignant melanoma. European Journal of Cancer, 2012, 48, 3052-3062.	2.8	17
190	Prevalence of germline <i>TP53</i> mutations and history of Li–Fraumeni syndrome in families with childhood adrenocortical tumors, choroid plexus tumors, and rhabdomyosarcoma: A populationâ€based survey. Pediatric Blood and Cancer, 2012, 59, 846-853.	1.5	17
191	Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT. Journal of the American Academy of Dermatology, 2019, 81, 386-394.	1.2	17
192	Desloratadine and loratadine use associated with improved melanoma survival. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2096-2099.	5.7	17
193	Reproductive factors in hereditary breast cancer. Breast Cancer Research and Treatment, 1999, 58, 293-299.	2.5	16
194	Sick leave of spouses to cancer patients before and after diagnosis. Acta Oncológica, 2010, 49, 467-473.	1.8	16
195	The association between weight at birth and breast cancer risk revisited using Mendelian randomisation. European Journal of Epidemiology, 2019, 34, 591-600.	5.7	16
196	The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma—Association with Clinical Outcome and Tumor Phenotypes. Cancers, 2019, 11, 1981.	3.7	16
197	Increased cancer risk in offspring of women with colorectal carcinoma. Cancer, 2000, 89, 741-749.	4.1	15
198	Relation between occupational exposure to organic solvents and chromosome aberrations in nonâ€Hodgkin's lymphoma. European Journal of Haematology, 1989, 42, 298-302.	2.2	15

#	Article	IF	CITATIONS
199	IGF1 htSNPs in relation to IGF-1 levels in young women from high-risk breast cancer families: implications for early-onset breast cancer. Familial Cancer, 2011, 10, 173-185.	1.9	15
200	Establishing a Southern Swedish Malignant Melanoma OMICS and biobank clinical capability. Clinical and Translational Medicine, 2013, 2, 7.	4.0	15
201	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2018, 47, 450-459.	1.9	15
202	A single exercise session improves side-effects of chemotherapy in women with breast cancer: an observational study. BMC Cancer, 2019, 19, 1073.	2.6	15
203	Physical activity and survival following breast cancer. European Journal of Cancer Care, 2019, 28, e13037.	1.5	15
204	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	5.0	15
205	Food Sources of Fat and Sex Hormone Receptor Status of Invasive Breast Tumors in Women of the Malmö Diet and Cancer Cohort. Nutrition and Cancer, 2011, 63, 722-733.	2.0	14
206	Prevalence of germline pathogenic variants in 22 cancer susceptibility genes in Swedish pediatric cancer patients. Scientific Reports, 2021, 11, 5307.	3.3	14
207	The human melanoma proteome atlas—Defining the molecular pathology. Clinical and Translational Medicine, 2021, 11, e473.	4.0	14
208	Occupational exposure to endocrine-disrupting compounds and biliary tract cancer among men. Scandinavian Journal of Work, Environment and Health, 2007, 33, 387-396.	3.4	14
209	CYTOGENETIC STUDIES IN HODGKIN'S DISEASE. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section A, Pathology, 1987, 95A, 289-295.	0.3	13
210	Distribution of aldehyde dehydrogenase 1â€positive stem cells in benign mammary tissue from women with and without breast cancer. Histopathology, 2012, 60, 617-633.	2.9	13
211	Women with familial risk for breast cancer have an increased frequency of aldehyde dehydrogenase expressing cells in breast ductules. BMC Clinical Pathology, 2013, 13, 28.	1.8	13
212	Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members ofAMelanoma Families. Journal of Investigative Dermatology, 2016, 136, 1066-1069.	0.7	13
213	CM-Score: a validated scoring system to predict <i>CDKN2A</i> germline mutations in melanoma families from Northern Europe. Journal of Medical Genetics, 2018, 55, 661-668.	3.2	13
214	Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma. Melanoma Research, 2019, 29, 483-490.	1.2	13
215	Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk. International Journal of Cancer, 2020, 146, 2130-2138.	5.1	13
216	Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables. Anticancer Research, 2004, 24, 2681-7.	1.1	13

#	Article	IF	CITATIONS
217	Blood Transfusion at Delivery and Risk of Subsequent Malignant Lymphoma in the Mother. Vox Sanguinis, 1998, 75, 145-148.	1.5	12
218	IGFBP1 and IGFBP3 polymorphisms predict circulating IGFBP-3 levels among women from high-risk breast cancer families. Breast Cancer Research and Treatment, 2011, 127, 785-794.	2.5	12
219	Lung cancer in young women in southern Sweden: A descriptive study. Clinical Respiratory Journal, 2018, 12, 1565-1571.	1.6	12
220	Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data. Scientific Reports, 2019, 9, 5154.	3.3	12
221	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
222	Common Susceptibility Loci for Male Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 453-461.	6.3	12
223	The need for oncogenetic counselling Ten years' experience of a regional oncogenetic clinic. Acta Oncológica, 2004, 43, 637-649.	1.8	11
224	Regression analysis and modelling of data acquisition for SELDI-TOF mass spectrometry. Bioinformatics, 2007, 23, 1401-1409.	4.1	11
225	Prolactin levels, breast-feeding and milk production in a cohort of young healthy women from high-risk breast cancer families: implications for breast cancer risk. Familial Cancer, 2008, 7, 221-228.	1.9	11
226	Expression of <i>Helix pomatia</i> Lectin Binding Glycoproteins in Women with Breast Cancer in Relationship to Their Blood Group Phenotypes. Journal of Proteome Research, 2009, 8, 782-786.	3.7	11
227	Increased mortality in prostate carcinoma and smoking-related disease after parietal cell vagotomy: A long-term follow-up study. Scandinavian Journal of Gastroenterology, 2009, 44, 947-951.	1.5	11
228	Plasma enterolactone and risk of prostate cancer in middle-aged Swedish men. European Journal of Nutrition, 2018, 57, 2595-2606.	3.9	11
229	Phenocopies in melanoma-prone families with germ-line CDKN2A mutations. Genetics in Medicine, 2018, 20, 1087-1090.	2.4	11
230	Prognostic factors in lung cancer in a defined geographical area over two decades with a special emphasis on gender. Clinical Respiratory Journal, 2013, 7, 91-100.	1.6	10
231	Phosphorylation and dephosphorylation of hormone-sensitive lipase Interactions between the regulatory and basal phosphorylation sites. FEBS Letters, 1988, 232, 78-82.	2.8	9
232	A review of the epidemiology of soft tissue sarcoma. Acta Orthopaedica, 1999, 70, 8-10.	1.4	9
233	High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: Implications for breast and ovarian cancer risk. Molecular Genetics and Metabolism, 2005, 86, 320-327.	1.1	9
234	A populationâ€based cohort study on the use of hormone treatment and endometrial cancer in southern Sweden. International Journal of Cancer, 2009, 125, 421-425.	5.1	9

#	Article	IF	CITATIONS
235	Feasibility Study on Measuring Selected Proteins in Malignant Melanoma Tissue by SRM Quantification. Journal of Proteome Research, 2014, 13, 1315-1326.	3.7	9
236	Endogenous expression mapping of malignant melanoma by mass spectrometry imaging. Clinical and Translational Medicine, 2018, 7, 22.	4.0	9
237	Novel functional proteins coded by the human genome discovered in metastases of melanoma patients. Cell Biology and Toxicology, 2020, 36, 261-272.	5.3	9
238	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	6.4	9
239	Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype. Melanoma Research, 2010, 20, 266-272.	1.2	8
240	Primary Melanoma Tumors from CDKN2A Mutation Carriers Do Not Belong to a Distinct Molecular Subclass. Journal of Investigative Dermatology, 2014, 134, 3000-3003.	0.7	8
241	Differences in IGFBP-3 regulation between young healthy women from BRCAX families and those belonging to BRCA1/2 families. European Journal of Cancer Prevention, 2006, 15, 233-241.	1.3	7
242	Increased incidence of childhood, prostate and breast cancers in relatives of childhood cancer patients. Familial Cancer, 2012, 11, 145-155.	1.9	7
243	Current smoking is associated with a larger waist circumference and a more androgenic profile in young healthy women from high-risk breast cancer families. Cancer Causes and Control, 2018, 29, 243-251.	1.8	7
244	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	5.0	7
245	Women with fair phenotypes seem to confer a survival advantage in a low UV milieu. A nested matched case control study. PLoS ONE, 2020, 15, e0228582.	2.5	7
246	Oral Contraceptive Use in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Absolute Cancer Risks and Benefits. Journal of the National Cancer Institute, 2022, 114, 540-552.	6.3	7
247	Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families. Familial Cancer, 2007, 6, 445-452.	1.9	6
248	Breast cancer patients with lobular cancer more commonly have a father than a mother diagnosed with cancer. BMC Cancer, 2011, 11, 497.	2.6	6
249	Impact of a paternal origin of germline <i>BRCA1</i> /2 mutations on the age at breast and ovarian cancer diagnosis in a Southern Swedish cohort. Genes Chromosomes and Cancer, 2015, 54, 39-50.	2.8	6
250	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. Human Genetics and Genomics Advances, 2021, 2, 100042.	1.7	6
251	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	6.2	6
252	Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65.	4.4	6

#	Article	IF	CITATIONS
253	A Genome-Wide Gene-Based Gene–Environment Interaction Study of Breast Cancer in More than 90,000 Women. Cancer Research Communications, 2022, 2, 211-219.	1.7	6
254	Analysis of Swedish male breast cancer family data: A simple way to incorporate a common sibling effect. , 1998, 15, 201-212.		5
255	C-band polymorphism in non-Hodgkin lymphoma. Hereditas, 2008, 103, 85-87.	1.4	5
256	Survival following combination chemotherapy in advanced high grade nonâ€Hodgkin's lymphomas: Relation to proliferative activity of the lymphoma cells. European Journal of Haematology, 1987, 38, 437-441.	2.2	5
257	Deletion of 14q in nonâ€Hodgkin's lymphoma. European Journal of Haematology, 1990, 44, 261-264.	2.2	5
258	Androgen receptor htSNPs in relation to androgen levels and OC use in young women from high-risk breast cancer families. Molecular Genetics and Metabolism, 2011, 102, 82-90.	1.1	5
259	Predominance of girls with cancer in families with multiple childhood cancer cases. BMC Cancer, 2017, 17, 868.	2.6	5
260	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	3.3	5
261	Women with a predisposition for diabetes have an increased risk of pregnancy complications, especially in combination with pregestational overweight. BMC Pregnancy and Childbirth, 2020, 20, 74.	2.4	5
262	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. British Journal of Cancer, 2021, 124, 842-854.	6.4	5
263	Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985. Cancer, 1997, 79, 275-283.	4.1	5
264	Evaluation of in vitro properties of films of saliva substitutes in contact with different surfaces A comparative study with instruments for measurements of friction and rheologic properties. Acta Odontologica Scandinavica, 1995, 53, 334-338.	1.6	4
265	Breakprone chromosome bands in fibroblasts from patients with non-Hodgkin's lymphoma do not coincide with bands involved in primary rearrangements in non-Hodgkin's lymphomas. Hereditas, 2008, 109, 131-137.	1.4	4
266	Normal frequency of structural chromosome aberrations in fibroblasts from patients with non-Hodgkin's lymphoma. Hereditas, 1988, 109, 277-280.	1.4	4
267	Can a phenotype for recessive inheritance in breast cancer be defined?. Familial Cancer, 2010, 9, 525-530.	1.9	4
268	Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer. SpringerPlus, 2013, 2, 357.	1.2	4
269	Stellate cells and mesenchymal stem cells in benign mammary stroma are associated with risk factors for breast cancer – an observational study. BMC Cancer, 2018, 18, 230.	2.6	4
270	Birth cohort-specific trends of sun-related behaviors among individuals from an international consortium of melanoma-prone families. BMC Public Health, 2021, 21, 692.	2.9	4

#	Article	IF	CITATIONS
271	Neuroendocrine differentiation in male breast carcinomas. Apmis, 1992, 100, 720-726.	2.0	3
272	Proliferative activity and number of clonal chromosome aberrations in non-Hodgkin's lymphomas. Scandinavian Journal of Haematology, 2009, 37, 106-110.	0.0	3
273	RELATIONSHIP BETWEEN CYTOGENETIC FINDINGS AND HISTOPATHOLOGY IN NONâ€HODGKIN LYMPHOMA. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section A, Pathology, 1987, 95A, 1-5.	0.3	3
274	Analysis of protein expression in pure cell nuclei populations isolated from human breast cancer tissue by DNA flow cytometric sorting. Journal of Proteomics, 2010, 73, 1111-1116.	2.4	3
275	Investigation of a putative melanoma susceptibility locus at chromosome 3q29. Cancer Genetics, 2014, 207, 70-74.	0.4	3
276	Rationale for a Swedish cohort consortium. Upsala Journal of Medical Sciences, 2019, 124, 21-28.	0.9	3
277	Problems in assessing multiple cutaneous melanoma. A review on the accuracy of a population based cancer registry. Cancer Epidemiology, 2010, 34, 262-266.	1.9	2
278	Oral contraceptive use, parity, and constitutional characteristics in soft tissue sarcoma: a Swedish population-based case–control study 1988–2009. Cancer Causes and Control, 2014, 25, 1167-1177.	1.8	2
279	Increased Cancer Risk in Families with Pediatric Cancer Is Associated with Gender, Age, Diagnosis, and Degree of Relation to the Child. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2171-2179.	2.5	2
280	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	3.3	2
281	Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes. Cancers, 2020, 12, 767.	3.7	2
282	Correlation between p53, câ€erbBâ€⊋, and topoisomerase Ilα expression, DNA ploidy, hormonal receptor status and proliferation in 356 nodeâ€negative breast carcinomas: prognostic implications. Journal of Pathology, 1999, 187, 207-216.	4.5	2
283	Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer, 1998, 83, 310-319.	4.1	2
284	Blood Transfusion at Delivery and Risk of Subsequent Malignant Lymphoma in the Mother. Vox Sanguinis, 1998, 75, 145-148.	1.5	2
285	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. Scientific Reports, 2021, 11, 19787.	3.3	2
286	Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. Scientific Reports, 2022, 12, 6199.	3.3	2
287	Breast cancer and spider telangiectasias at diagnosis and its relation to histopathology and prognosis: a population-based study. Breast Cancer Research and Treatment, 2012, 131, 177-186.	2.5	1
288	The absence of aldehyde dehydrogenase 1 A1-positive cells in benign mammary stroma is associated with risk factors for breast cancer. Breast Cancer: Targets and Therapy, 2016, 8, 117.	1.8	1

#	Article	IF	CITATIONS
289	Variations in the Referral Pattern for Genetic Counseling of Patients with Early-Onset Breast Cancer: A Population-Based Study in Southern Sweden. Public Health Genomics, 2020, 23, 100-109.	1.0	1
290	Genetic testing in women with early-onset breast cancer: a Traceback pilot study. Breast Cancer Research and Treatment, 2021, 190, 307-315.	2.5	1
291	Correlation between p53, c-erbB-2, and topoisomerase $Il\hat{I}\pm$ expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. , 0, .		1
292	Increased cancer risk in offspring of women with colorectal carcinoma. Cancer, 2000, 89, 741-749.	4.1	1
293	High frequency of microsatellite instability and loss of mismatchâ€repair protein expression in patients with double primary tumors of the endometrium and colorectum. Cancer, 2002, 94, 2502-2510.	4.1	1
294	Women Who Develop Diabetes Later in Life Have Diabetes-Associated Complications during Preceding Pregnancies. Journal of Diabetes Mellitus, 2014, 04, 341-349.	0.3	1
295	PARTIAL PURIFICATION AND PROPERTIES OF A PROTEIN PHOSPHATASE FROM RAT ADIPOSE TISSUE. Biochemical Society Transactions, 1981, 9, 237P-237P.	3.4	0
296	The prognostic implication of cytogenetic findings in non-Hodgkin lymphomas. Clinical Genetics, 2008, 29, 464-464.	2.0	0
297	Abstract A127: Parental influence on breast cancer penetrance inBRCA1/2mutation carriers: Impact of oral contraceptive use before age 20 years. , 2013, , .		0